Education
About Us
Working with TipRanks
Follow Us
Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
CNTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $2.29
Previous CloseN/A
Volume1.98K
Average Volume (3M)58.45K
Market Cap
$32.66M
Enterprise Value-$17.37M
Total Cash (Recent Filing)$44.82M
Total Debt (Recent Filing)$127.96K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Sep 16, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding55,349,210
10 Day Avg. Volume134,487
30 Day Avg. Volume58,454
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.58
Enterprise Value/Ebitda0.17
Forecast
1Y Price Target
$8.00Price Target Upside1255.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Connect Biopharma Holdings News
PremiumCompany Announcements
Connect Biopharma Gains FDA Support for Phase 2 Trials
PremiumCompany Announcements
Connect Biopharma’s Strategic Advances and Financial Outlook
PremiumCompany Announcements
Connect Biopharma Receives Nasdaq Deficiency Notice
PremiumCompany Announcements
Connect Biopharma Appoints New Accounting FirmPremiumCompany Announcements
Connect Biopharma Welcomes New Finance VP---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCompany has updated its timing for initial data from both trials to 1H26, from 2H26 previously reported, which is a positive update given the creation of a meaningful catalyst within ~12 months.
Market CompetitionConnect Biopharma is planning a Phase 2 trial for rademikibart to treat acute exacerbations due to asthma or COPD, which is a market with no existing competition from approved drugs like Dupixent.
Operational EfficiencyThe company's restructuring to focus on the US market, including relocating its headquarters to San Diego, is aimed at enhancing its market presence and operational efficiency.
Regulatory ApprovalFDA acknowledged the unmet need for reducing recurrent exacerbations following an acute exacerbation of asthma or COPD which occurs in up to 50% of cases.
Bears Say
Clinical RisksRisks include safety signals emerge with any of the company’s clinical or preclinical programs, efficacy from clinical programs is lower than expected, or the company’s studies do not achieve statistical significance.
FinancingFinancing requirements for the business assume cash runway into 2027 and approximately $150M additional financing needed through 2038.
---
Ownership Overview
11.70%
Insiders
0.05% Mutual Funds
4.94% Other Institutional Investors
83.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.55 and its highest was $2.29 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $32.66M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Sep 16, 2025 which is in 164 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Mar 31, 2025. The company reported -$0.418 earnings per share for the quarter, missing the consensus estimate of -$0.259 by -$0.159.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.37.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 55,349,210 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.418 in its last earnings report, missing expectations of -$0.259. Following the earnings report the stock price went down -19.118%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
---
Connect Biopharma Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (1255.93% Upside)
$8.00 (1255.93% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.30%
12-Months-Change
Fundamentals
Return on Equity
-58.89%
Trailing 12-Months
Asset Growth
-15.87%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
---
CNTB Stock 12 Month Forecast
Average Price Target
$8.00
▲(1255.93% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Allogene Therapeutics
―
Best Analysts Covering CNTB
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
-8.45%
reiterated a buy rating 12 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -8.45% per trade.
---